CA3164022A1 - Use of intranasal racemic ketamine to treat suicidality and major depression - Google Patents

Use of intranasal racemic ketamine to treat suicidality and major depression Download PDF

Info

Publication number
CA3164022A1
CA3164022A1 CA3164022A CA3164022A CA3164022A1 CA 3164022 A1 CA3164022 A1 CA 3164022A1 CA 3164022 A CA3164022 A CA 3164022A CA 3164022 A CA3164022 A CA 3164022A CA 3164022 A1 CA3164022 A1 CA 3164022A1
Authority
CA
Canada
Prior art keywords
hours
racemic ketamine
pharmaceutically acceptable
acceptable salt
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3164022A
Other languages
English (en)
French (fr)
Inventor
Raj Mehra
Timothy Whitaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seelos Therapeutics Inc
Original Assignee
Seelos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seelos Therapeutics Inc filed Critical Seelos Therapeutics Inc
Publication of CA3164022A1 publication Critical patent/CA3164022A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3164022A 2020-01-22 2021-01-22 Use of intranasal racemic ketamine to treat suicidality and major depression Pending CA3164022A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062964598P 2020-01-22 2020-01-22
US62/964,598 2020-01-22
US202063079791P 2020-09-17 2020-09-17
US63/079,791 2020-09-17
PCT/US2021/014748 WO2021150985A1 (en) 2020-01-22 2021-01-22 Reducing side effects of nmda antagonists

Publications (1)

Publication Number Publication Date
CA3164022A1 true CA3164022A1 (en) 2021-07-29

Family

ID=74672414

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3164022A Pending CA3164022A1 (en) 2020-01-22 2021-01-22 Use of intranasal racemic ketamine to treat suicidality and major depression

Country Status (14)

Country Link
US (5) US20230064327A1 (https=)
EP (1) EP4093388A1 (https=)
JP (2) JP2023511370A (https=)
KR (1) KR20220137033A (https=)
CN (2) CN115135317A (https=)
AU (1) AU2021210405A1 (https=)
BR (1) BR112022014382A2 (https=)
CA (1) CA3164022A1 (https=)
CL (1) CL2022001958A1 (https=)
IL (1) IL294485A (https=)
MX (1) MX2022009050A (https=)
PH (1) PH12022551856A1 (https=)
TW (1) TW202139981A (https=)
WO (1) WO2021150985A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056378T2 (hu) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
US11980595B2 (en) 2018-02-15 2024-05-14 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
WO2019213551A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
JP2023511370A (ja) 2020-01-22 2023-03-17 シーロス セラピューティクス， インコーポレイテッド Ｎｍｄａ拮抗薬の副作用の低減
US20240261236A1 (en) * 2021-05-14 2024-08-08 Seelos Therapeutics, Inc. Methods of using nmda receptor antagonists
TW202310825A (zh) * 2021-05-14 2023-03-16 美商西羅斯醫療公司 減少ｎｍｄａ受體拮抗劑之副作用
WO2025240537A1 (en) * 2024-05-13 2025-11-20 Gilgamesh Pharmaceuticals, Inc. Methods of treating psychiatric disorders or pain using (r)-2-(4-fluorophenyl)-2-(methylamino)cyclohexan-1-one or pharmaceutically acceptable salts thereof
CN120919139A (zh) * 2025-09-09 2025-11-11 徐州百瑞麻醉科技研究院有限公司 一种抗抑郁药物组合物及其应用

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3760077A (en) 1969-02-18 1973-09-18 Cutter Lab Injectable compositions of the (plus)-optical isomer of the alpha racemate of 2-(2-ethyl-2-phenyl-1, -dioxolan-4-yl)piperidine and their use
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
US4017619A (en) 1973-10-26 1977-04-12 Burnap Raymond W Anesthetic and sedative composition
EP0424179A3 (en) 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
GB9020544D0 (en) 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US6350784B1 (en) 1996-02-12 2002-02-26 Meryl J. Squires Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5321012A (en) 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5352683A (en) 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5679714A (en) 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
US5683709A (en) 1994-05-05 1997-11-04 Ciba Vision Corporation Poly(benzalkonium salt) as an anti-microbial agent for aqueous drug compositions
US5604244A (en) 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
CA2230690C (en) 1995-08-30 2008-12-23 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6197830B1 (en) 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
DE19601782A1 (de) 1996-01-19 1997-07-24 Merck Patent Gmbh Chinolin-2-(1H)one
US5688830A (en) 1996-01-25 1997-11-18 Syntex (U.S.A.) Inc. Treatment of neuropathic pain
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US5919826A (en) 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6124282A (en) 1997-05-22 2000-09-26 Sellers; Edward M. Drug formulations
US5817699A (en) 1997-05-30 1998-10-06 Flores; John A. Process for the preparation of ketamine ointment
US6329429B1 (en) 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
FR2772271B1 (fr) 1997-12-11 2000-09-01 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
JP2002528416A (ja) 1998-10-27 2002-09-03 アルコン ラボラトリーズ， インコーポレーテッド 外網膜の疾患の治療
AU1602100A (en) 1998-11-25 2000-06-13 Warner-Lambert Company Improved gamma amino butyric acid analogs
WO2000035876A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
US6200990B1 (en) 1998-12-21 2001-03-13 Alcon Laboratories, Inc. Neuroprotective agents having antioxidant and NMDA antagonist activity
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
YU41202A (sh) 1999-12-28 2005-03-15 Pfizer Products Inc. Ne-peptidni inhibitori vezivanja za ćeliju zavisnog od vla-4 korisni pri tretiranju inflamatornih, autoimunih i respiratornih bolesti
IL152473A0 (en) 2000-04-28 2003-05-29 Sloan Kettering Inst Cancer Topical anesthetic/opioid formulations and uses thereof
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US6878751B1 (en) 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
US20040122090A1 (en) 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
MXPA03004652A (es) 2000-12-21 2003-09-05 Warner Lambert Co Derivados de piperidina como antagonistas selectivos de subtipo de n-metil-d-aspartato.
WO2002066015A1 (en) 2001-02-16 2002-08-29 Bristol-Myers Squibb Pharma Company Use of polyalkylamine polymers in controlled release devices
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
CA2456806C (en) 2001-08-08 2011-10-18 Brown University Research Foundation Methods for micronization of hydrophobic drugs
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
US20040039352A1 (en) 2002-06-28 2004-02-26 Paul Bergeson Nasal dosing device
GB0215270D0 (en) 2002-07-02 2002-08-14 Optinose As Nasal devices
US20050148673A1 (en) 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
EP1558231A4 (en) 2002-10-03 2010-09-08 Cypress Bioscience Inc DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
DE10306686A1 (de) 2003-02-12 2004-08-26 Ing. Erich Pfeiffer Gmbh Austragvorrichtung zur manuellen Erzeugung eines Volumenstroms
US20040266808A1 (en) 2003-06-27 2004-12-30 Kamen Barton A. Treatment of antifolate neurotoxicity
GB0319119D0 (en) 2003-08-14 2003-09-17 Optinose As Delivery devices
WO2005058911A2 (en) 2003-12-15 2005-06-30 Alcon, Inc. Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
WO2005079756A2 (en) 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
US20050222270A1 (en) 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
GB0420513D0 (en) 2004-09-15 2004-10-20 Optinose As Powder delivery devices
AU2004100927B4 (en) 2004-11-01 2005-03-24 Richard Benson Snorenomore (anti-snoring device)
GB0503738D0 (en) 2005-02-23 2005-03-30 Optinose As Powder delivery devices
GB0604444D0 (en) 2006-03-06 2006-04-12 Optinose As Nasal devices
AU2007229866A1 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
US7506649B2 (en) 2006-06-07 2009-03-24 Ventus Medical, Inc. Nasal devices
US8607228B2 (en) 2006-08-08 2013-12-10 Intel Corporation Virtualizing performance counters
GB0623732D0 (en) 2006-11-28 2007-01-10 Optinose As Powder delivery devices
GB2448193A (en) 2007-04-05 2008-10-08 Optinose As Nasal delivery device
BRPI0809843A2 (pt) 2007-04-26 2014-09-23 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
AU2008279169A1 (en) 2007-07-23 2009-01-29 Biotie Therapies, Inc 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
GB0719299D0 (en) 2007-10-03 2007-11-14 Optinose As Nasal delivery devices
TW201029689A (en) 2008-11-03 2010-08-16 Schering Corp Elastomeric discharge member for nasal delivery device
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US8875711B2 (en) 2010-05-27 2014-11-04 Theravent, Inc. Layered nasal respiratory devices
AP2012006639A0 (en) 2010-06-04 2012-12-31 Us Gov Ct Disease Contr & Prev Nasal aerosol delivery system
JP3193069U (ja) 2010-09-02 2014-09-18 シプノーズ リミテッド 経鼻投与装置
GB201015371D0 (en) 2010-09-14 2010-10-27 Optinose As Nasal delivery
WO2012123819A1 (en) 2011-03-15 2012-09-20 Optinose As Et Al Nasal delivery
US8791091B2 (en) 2011-12-02 2014-07-29 Bristol-Myers Squibb Company Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
PL2817054T3 (pl) 2012-02-24 2020-12-14 Optinose As Donosowe urządzenia podające
PL2817052T3 (pl) 2012-02-24 2018-01-31 Optinose As Urządzenia do podawania donosowego
CA2865355C (en) 2012-02-24 2021-02-16 Optinose As Nasal delivery devices
WO2013128447A1 (en) 2012-02-28 2013-09-06 Sipnose Ltd. Nasal delivery device
ES1076654Y (es) 2012-03-15 2012-07-03 Garcia Miguel Ramon Guillem Aspirador nasal.
KR20150096370A (ko) 2012-08-23 2015-08-24 스튜어트 엘. 웨그 항불안제 조성물, 제형 및 사용방법
FR3003481B1 (fr) 2013-03-19 2020-05-15 Aptar France Sas Dispositif de distribution de produit fluide.
US10596334B2 (en) 2013-04-04 2020-03-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nasal aerosol delivery system
DK2983787T3 (da) 2013-04-12 2020-01-06 Icahn School Med Mount Sinai Fremgangsmåde til behandling af posttraumatisk stresssygdom
FR3016123B1 (fr) 2014-01-03 2016-02-05 Georges Creps Dispositif nasal ambulatoire ameliore
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
WO2016109427A1 (en) 2014-12-31 2016-07-07 Icahn School Of Medicine At Mount Sinai Method of maintaining the anti-depressant effect of ketamine with lithium
US20160199599A1 (en) 2015-01-13 2016-07-14 Bhl Patent Holdings Llc Nasal Delivery Device and Methods of Use
WO2016172672A1 (en) * 2015-04-24 2016-10-27 Icahn School Of Medicine At Mount Sinai Method for treating suicidal ideation
US20160361507A1 (en) 2015-06-11 2016-12-15 Bruce H. Levin Nasal Delivery Device and Methods of Use
AU2016302387B2 (en) 2015-07-31 2020-12-24 Asap Breatheassist Pty Ltd Nasal devices
MX2018002895A (es) 2015-09-10 2018-07-06 Impel Neuropharma Inc Dispositivo de administracion nasal en linea.
US10940274B2 (en) 2015-12-01 2021-03-09 Cipla Limited Nasal spray assembly
FR3046552B1 (fr) 2016-01-07 2018-02-16 Aptar France Sas Dispositif de distribution nasale de poudre.
EP3426329A4 (en) 2016-03-09 2019-11-13 Proveris Scientific Corporation METHOD FOR MEASURING THE UNITABILITY OF THE DOSE CONTENT OF INHALATION AND NOSING DEVICES
CN110177545A (zh) 2016-11-16 2019-08-27 爱尔兰詹森科学公司 用于预防上呼吸道感染的聚肌苷酸和聚胞苷酸的制剂
US20180177743A1 (en) 2016-12-22 2018-06-28 Gary Jay Method of treating pain using racemic mixture of s-ketamine and r-ketamine
US20180256867A1 (en) 2017-03-07 2018-09-13 Bruce H. Levin Nasal Delivery Device and Methods of Use
SE542541C2 (en) 2017-05-12 2020-06-02 Noseoption Ab Nasal device
WO2019077586A1 (en) 2017-10-20 2019-04-25 Beck Medical, Ltd. NASAL DEVICE FOR TREATMENT
TWI660756B (zh) 2018-05-22 2019-06-01 蔡淑真 Nasal inserter
TWI673076B (zh) 2018-12-28 2019-10-01 蔡淑真 鼻腔插入器
JP2022524008A (ja) 2019-03-05 2022-04-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のためのエスケタミン
CA3133012A1 (en) 2019-08-05 2021-02-11 The Ketamine Research Foundation Ketamine for the treatment of postpartum symptoms and disorders
JP2023511370A (ja) 2020-01-22 2023-03-17 シーロス セラピューティクス， インコーポレイテッド Ｎｍｄａ拮抗薬の副作用の低減
TW202310825A (zh) 2021-05-14 2023-03-16 美商西羅斯醫療公司 減少ｎｍｄａ受體拮抗劑之副作用
US20240261236A1 (en) 2021-05-14 2024-08-08 Seelos Therapeutics, Inc. Methods of using nmda receptor antagonists

Also Published As

Publication number Publication date
TW202139981A (zh) 2021-11-01
US20240342113A1 (en) 2024-10-17
BR112022014382A2 (pt) 2022-09-13
AU2021210405A1 (en) 2022-08-25
EP4093388A1 (en) 2022-11-30
CN121489916A (zh) 2026-02-10
JP2023511370A (ja) 2023-03-17
US20230270694A1 (en) 2023-08-31
PH12022551856A1 (en) 2024-01-03
KR20220137033A (ko) 2022-10-11
US12440457B2 (en) 2025-10-14
JP2026050474A (ja) 2026-03-19
IL294485A (en) 2022-09-01
US20230241008A1 (en) 2023-08-03
US20230064327A1 (en) 2023-03-02
MX2022009050A (es) 2022-10-27
CN115135317A (zh) 2022-09-30
WO2021150985A1 (en) 2021-07-29
CL2022001958A1 (es) 2023-05-26
US20230321007A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
US12440457B2 (en) Methods of treating suicidality
US8461148B2 (en) Use of memantine (namenda) to treat autism, compulsivity and impulsivity
KR20150142012A (ko) 외상후 스트레스 장애의 치료 방법
US20240325296A1 (en) Esketamine for the treatment of depression
US20220071989A1 (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
JP2007526335A (ja) 焦燥およびその他の行動障害、特にアルツハイマー病に関連する行動障害の治療用１−アミノシクロヘキサン誘導体
JP2022548233A (ja) エスケタミンの鼻腔内投与
US20240261237A1 (en) Reducing side effects of nmda receptor antagonists
US20240261236A1 (en) Methods of using nmda receptor antagonists
WO2024216046A1 (en) Methods of treating anhedonia
EA046262B1 (ru) Уменьшение побочных эффектов антагонистов n-метил-d-аспартата (nmda)
CN119654149A (zh) 用于在治疗抑郁障碍中使用的奥法地尔的皮下施用和给药方法
HK40081090A (en) Reducing side effects of nmda antagonists
TW200916091A (en) Neramexane for the treatment of nystagmus
US20240350433A1 (en) Treatment compositions and methods
Buffum et al. The psychopharmacologic treatment of depression in elders: Medical conditions, life circumstances, and the type and number of medications currently taken are considerations in selecting an anti-depressant medication

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220912

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250717

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250717

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251008

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251028

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20251223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251223

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251224

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260204

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260205

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260205

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260312